1-deoxynojirimycin has been researched along with anagliptin in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goda, T; Harazaki, T; Imai, C; Inoue, S; Mochizuki, K | 2 |
| Kishimoto, M; Noda, M | 1 |
| Goto, M; Hariya, N; Mochizuki, K; Osonoi, T; Saito, M | 1 |
1 trial(s) available for 1-deoxynojirimycin and anagliptin
| Article | Year |
|---|---|
Add-on therapy with anagliptin in Japanese patients with type-2 diabetes mellitus treated with metformin and miglitol can maintain higher concentrations of biologically active GLP-1/total GIP and a lower concentration of leptin.
Topics: 1-Deoxynojirimycin; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Leptin; Male; Metformin; Middle Aged; Pyrimidines; Treatment Outcome | 2016 |
3 other study(ies) available for 1-deoxynojirimycin and anagliptin
| Article | Year |
|---|---|
Inhibition of postprandial hyperglycemia by either an insulin-dependent or -independent drug reduces the expression of genes related to inflammation in peripheral leukocytes of OLETF rats.
Topics: 1-Deoxynojirimycin; alpha-Glucosidases; Animals; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Gene Expression; Hyperglycemia; Hypoglycemic Agents; Inflammation; Insulin; Interleukin-18; Interleukin-1beta; Leukocytes, Mononuclear; Male; Pyrimidines; Rats; Rats, Inbred OLETF; Receptors, Interleukin-1; S100 Proteins; Sucrose; TNF Receptor-Associated Factor 2 | 2013 |
Additive effects of miglitol and anagliptin on insulin-treated type 2 diabetes mellitus: a case study.
Topics: 1-Deoxynojirimycin; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pyrimidines | 2015 |
Treatment with DPP-4I Anagliptin or α-GI Miglitol Reduces IGT Development and the Expression of CVD Risk Factors in OLETF Rats.
Topics: 1-Deoxynojirimycin; Animals; Aorta; Blood Glucose; Cardiovascular Diseases; Cell Adhesion Molecules; Cytokines; Fasting; Hyperglycemia; Hypoglycemic Agents; Interleukin-1beta; Leukocytes; Male; Postprandial Period; Pyrimidines; Rats; Rats, Inbred OLETF; Risk Factors; S100 Proteins; Tumor Necrosis Factor-alpha | 2015 |